Literature DB >> 20113909

Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia.

Nevins W Todd1, Sachin Lavania, Myung H Park, Aldo T Iacono, Teri J Franks, Jeffrey R Galvin, Jean Jeudy, Edward J Britt, Irina G Luzina, Jeffrey D Hasday, Sergei P Atamas.   

Abstract

BACKGROUND: Pulmonary hypertension may occur in patients with interstitial pneumonia and is associated with increased mortality. We sought to determine the prevalence of pulmonary hypertension in sub-groups of patients with interstitial pneumonia and to investigate possible associations between pulmonary vascular hemodynamics and pulmonary function.
METHODS: The presence or absence of pulmonary hypertension was assessed in 70 patients with advanced interstitial pneumonia who underwent right heart catheterization. The associations of pulmonary hypertension with clinical characteristics and pulmonary function tests were analyzed.
RESULTS: The prevalence of pulmonary hypertension in patients with idiopathic interstitial pneumonia was 29% vs 64% in patients with connective tissue disease-interstitial pneumonia (p = 0.013). African American patients had a significantly higher prevalence of pulmonary hypertension in the entire study population (81% vs 22%, p < 0.001) and in the idiopathic interstitial pneumonia group (70% vs 19%, p < 0.01). Regression analyses revealed no association between mean pulmonary artery pressure (mPAP) and forced vital capacity or mPAP and diffusion capacity of the lung for carbon monoxide in the entire cohort or in sub-groups of patients.
CONCLUSIONS: African American patients and patients with connective tissue disease-interstitial pneumonia had a high prevalence of pulmonary hypertension. Non-African American patients with advanced idiopathic interstitial pneumonia (including idiopathic pulmonary fibrosis) had a low prevalence of pulmonary hypertension.

Entities:  

Mesh:

Year:  2010        PMID: 20113909      PMCID: PMC2818153          DOI: 10.1016/j.healun.2009.07.025

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  21 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Authors:  Nazzareno Galiè; Adam Torbicki; Robyn Barst; Philippe Dartevelle; Sheila Haworth; Tim Higenbottam; Horst Olschewski; Andrew Peacock; Giuseppe Pietra; Lewis J Rubin; Gerald Simonneau; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin Cowie; Verconcia Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; Keith McGregor; João Morais; Ali Oto; Otto A Smiseth; Joan Albert Barbera; Simon Gibbs; Marius Hoeper; Marc Humbert; Robert Naeije; Joanna Pepke-Zaba
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

3.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

4.  Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis.

Authors:  T P M Whelan; J M Dunitz; R F Kelly; L B Edwards; C S Herrington; M I Hertz; P S Dahlberg
Journal:  J Heart Lung Transplant       Date:  2005-09       Impact factor: 10.247

Review 5.  Pulmonary arterial hypertension associated to connective tissue diseases.

Authors:  N Galiè; A Manes; K V Farahani; F Pelino; M Palazzini; L Negro; S Romanazzi; A Branzi
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001.

Authors:  R Hesselstrand; R Ekman; J Eskilsson; A Isaksson; A Scheja; A-K Ohlin; A Akesson
Journal:  Rheumatology (Oxford)       Date:  2004-11-23       Impact factor: 7.580

7.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Hassan F Nadrous; Patricia A Pellikka; Michael J Krowka; Karen L Swanson; Nithima Chaowalit; Paul A Decker; Jay H Ryu
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

9.  Increased mortality in African Americans with idiopathic pulmonary arterial hypertension.

Authors:  Kala K Davis; David E Lilienfeld; Ramona L Doyle
Journal:  J Natl Med Assoc       Date:  2008-01       Impact factor: 1.798

10.  Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.

Authors:  Robin Condliffe; David G Kiely; Andrew J Peacock; Paul A Corris; J Simon R Gibbs; Florenc Vrapi; Clare Das; Charlie A Elliot; Martin Johnson; Julia DeSoyza; Chantal Torpy; Kim Goldsmith; Denise Hodgkins; Rodney J Hughes; Joanna Pepke-Zaba; J Gerry Coghlan
Journal:  Am J Respir Crit Care Med       Date:  2008-10-17       Impact factor: 21.405

View more
  5 in total

1.  Interleukin-33 potentiates bleomycin-induced lung injury.

Authors:  Irina G Luzina; Pavel Kopach; Virginia Lockatell; Phillip H Kang; Ashish Nagarsekar; Allen P Burke; Jeffrey D Hasday; Nevins W Todd; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

Review 2.  [Chronic critically ill patients from a pneumological perspective].

Authors:  M Pfeifer
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-04-12       Impact factor: 0.840

3.  Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up.

Authors:  Anastase Dzudie; Bonaventure Suiru Dzekem; Cabral Tantchou Tchoumi; Leopold Ndemnge Aminde; Ana O Mocumbi; Martin Abanda; Friedrich Thienemann; Andre Pascal Kengne; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2018-07-07       Impact factor: 1.167

Review 4.  Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension.

Authors:  Sylvia M Nikkho; Manuel J Richter; Eric Shen; Steven H Abman; Katerina Antoniou; Jonathan Chung; Peter Fernandes; Paul Hassoun; Howard M Lazarus; Horst Olschewski; Lucilla Piccari; Mitchell Psotka; Rajan Saggar; Oksana A Shlobin; Norman Stockbridge; Patrizio Vitulo; Carmine Dario Vizza; Stephen J Wort; Steven D Nathan
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

5.  Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.

Authors:  Padmanabha D Shenoy; Manish Bavaliya; Sujith Sashidharan; Kaveri Nalianda; Sreelakshmi Sreenath
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.